BioSpace News Archive

BioCryst Pharmaceuticals, Inc. announced the completion of an underwritten public offering of 22,044,447 shares of its common stock, including 3,333,334 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares, and of pre-funded warrants to purchase up to an aggregate of 3,511,111 shares of common stock.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced today that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will present a company overview at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 2:30 pm Eastern time.

Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 228,175 shares of common stock and 63,125 restricted stock units to be distributed among 16 new employees with a grant date of June 1, 2020.

Technological advancements in the medical world and rising prevalence of foodborne diseases will primarily build the market for allergic rhinitis treatment globally.

Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced the commencement of a proposed underwritten public offering of 10,000,000 shares of its common stock.

Harbour BioMed (HBM) today announced that National Medical Products Administration (NMPA, China) approved its IND application for HBM9161, a full-human antibody targeting neonatal Fc receptor (FcRn), to conduct a Phase 2/3 clinical trial in patients with Graves’ ophthalmopathy (GO).

Study Demonstrates 5-Day Treatment Course of Remdesivir Resulted in Significantly Greater Clinical Improvement Versus Treatment with Standard of Care Alone -- -- Data Add to Body of Evidence from Prior Studies Demonstrating Benefit of Remdesivir in Hospitalized Patients with COVID-19 -- FOSTER CITY, Calif.--( BUSINESS WIRE )-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the Phase 3 SIMPLE trial in hospitaliz

The World’s First Alexandrite-ND: YAG System Now Upgraded with Skintel®, The Industry’s Only Melanin Reader™ For More Customized Laser Hair Removal Treatments For All Skin Types [01-June-2020] WESTFORD, Mass. , June 1, 2020 /PRNewswire/ -- Cynosure announced today the U.S., European and Australian launch of the Elite iQ ™ platform , the next generation of the Elite+

Latest-Generation Duodenoscope Offers Advanced Visualization, More Precise Handling, and Innovative Infection Prevention Features

Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced that RADICAVA ® (edaravone) is now listed on the Alberta Drug Benefit List formulary (special authorization). RADICAVA is an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS), a rapidly progressive, neur